EGFR and ovarian carcinoma: Yet, recent clinical trials targeting EGFR using cetuximab [16-18], matuzumab [19,20], gefitinib [21], and erlotinib [22,23] in epithelial ovarian cancer patients have shown only modest clinical responsiveness.